Relay Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Relay Therapeutics
RLAY Stock  USD 3.75  0.07  1.90%   
Relay Therapeutics financial statements provide useful quarterly and yearly information to potential Relay Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Relay Therapeutics financial statements helps investors assess Relay Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Relay Therapeutics' valuation are summarized below:
Gross Profit
-314.9 M
Market Capitalization
616 M
Enterprise Value Revenue
18.1672
Revenue
10 M
Earnings Share
(2.61)
We have found one hundred twenty available trending fundamental ratios for Relay Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Relay Therapeutics recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 1.1 B in 2025. Enterprise Value is likely to drop to about 683.8 M in 2025

Relay Therapeutics Total Revenue

20.65 Million

Check Relay Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Relay Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 37.5 M, Interest Income of 37.5 M or Depreciation And Amortization of 4 M, as well as many indicators such as Price To Sales Ratio of 45.17, Dividend Yield of 0.0 or PTB Ratio of 1.0. Relay financial statements analysis is a perfect complement when working with Relay Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Relay Therapeutics Correlation against competitors.
For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.

Relay Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets838.5 M970.6 M613.2 M
Slightly volatile
Short and Long Term Debt Total33.6 M61.5 M17.5 M
Slightly volatile
Other Current Liabilities1.3 M1.4 M4.1 M
Slightly volatile
Total Current Liabilities27.6 M34.8 M16.8 M
Slightly volatile
Other Liabilities21.6 M37.2 M12.1 M
Slightly volatile
Property Plant And Equipment Net43.2 M79.2 M24.2 M
Slightly volatile
Current Deferred Revenue18 M17.1 M5.7 M
Slightly volatile
Accounts Payable8.5 M10.6 M6.4 M
Slightly volatile
Cash157 M165.3 M419.1 M
Very volatile
Non Current Assets Total46.4 M85 M26.3 M
Slightly volatile
Non Currrent Assets Other1.8 M3.1 M1.3 M
Slightly volatile
Other Assets1.5 M3 M1.3 M
Slightly volatile
Cash And Short Term Investments763.1 M862.6 M572.5 M
Slightly volatile
Common Stock Total Equity71.9 K139.2 K42.7 K
Slightly volatile
Common Stock Shares Outstanding148 M141 M43 M
Slightly volatile
Liabilities And Stockholders Equity838.5 M970.6 M613.2 M
Slightly volatile
Non Current Liabilities Total52.8 M55.5 M357.5 M
Slightly volatile
Capital Surpluse2.4 B2.3 B729.4 M
Slightly volatile
Capital Lease Obligations33.6 M61.5 M17.5 M
Slightly volatile
Other Current Assets3.6 M3.8 M4.8 M
Slightly volatile
Total Liabilities78.6 M82.8 M373.7 M
Slightly volatile
Property Plant And Equipment Gross53.5 M106.3 M30.1 M
Slightly volatile
Total Current Assets792.1 M885.6 M586.9 M
Slightly volatile
Capital Stock83.2 K146.1 K44.2 K
Slightly volatile
Non Current Liabilities Other28.5 M15.2 M12.7 M
Slightly volatile
Net Working Capital764.5 M850.8 M570.2 M
Slightly volatile
Short Term Debt4 M5.7 M2 M
Slightly volatile
Common Stock83.2 K146.1 K44.2 K
Slightly volatile
Property Plant Equipment13.2 M10.5 M9.2 M
Slightly volatile
Intangible Assets1.8 M2.1 M2.3 M
Slightly volatile

Relay Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income37.5 M35.7 M8.5 M
Slightly volatile
Interest Income37.5 M35.7 M8.5 M
Slightly volatile
Depreciation And Amortization4 M6.1 M3.1 M
Slightly volatile
Selling General Administrative47.6 M86.2 M29 M
Slightly volatile
Other Operating Expenses481.2 M458.3 M159.5 M
Slightly volatile
Research Development398.5 M379.5 M129.2 M
Slightly volatile
Total Operating Expenses481.2 M458.3 M159.5 M
Slightly volatile
Reconciled Depreciation4 M6.1 M3.1 M
Slightly volatile
Total Other Income Expense Net37.5 M35.7 M8.5 M
Slightly volatile
Cost Of Revenue4.3 M6.1 M3.5 M
Slightly volatile
Non Operating Income Net Other10.6 M10.1 M4.6 M
Slightly volatile
Non Recurring98.4 M110.7 M120.7 M
Slightly volatile
Selling And Marketing Expenses3.4 M3.8 M4.2 M
Slightly volatile

Relay Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock1.4 M1.5 M249.7 M
Slightly volatile
Stock Based Compensation103.9 M98.9 M28.5 M
Slightly volatile
Begin Period Cash Flow261.1 M177.5 M153 M
Slightly volatile
Other Cashflows From Financing Activities3.8 M4 M224 M
Slightly volatile
Depreciation4 M6.1 M3.1 M
Slightly volatile
Capital Expenditures5.2 M4.7 M3.2 M
Slightly volatile
Issuance Of Capital Stock8 M8.4 M292.1 M
Slightly volatile
Total Cash From Financing Activities29.7 M31.3 M297.5 M
Slightly volatile
End Period Cash Flow199.6 M131.8 M325.5 M
Slightly volatile
Change To Netincome67.8 M64.6 M22.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio45.1747.55160
Slightly volatile
Days Sales Outstanding7901.2 K746
Slightly volatile
Stock Based Compensation To Revenue2.883.034.3861
Slightly volatile
Capex To Depreciation1.460.91.0392
Slightly volatile
EV To Sales53.8656.6995.4827
Slightly volatile
Payables Turnover0.380.510.4633
Very volatile
Sales General And Administrative To Revenue2.512.644.9963
Slightly volatile
Research And Ddevelopement To Revenue11.0511.6317.7673
Slightly volatile
Capex To Revenue0.140.150.526
Slightly volatile
Cash Per Share6.697.04105
Slightly volatile
Days Payables Outstanding860734791
Very volatile
Income Quality1.031.010.9305
Very volatile
Intangibles To Total Assets0.00190.00250.0023
Very volatile
Net Debt To EBITDA0.260.285.9879
Slightly volatile
Current Ratio42.1529.2649.7227
Slightly volatile
Receivables Turnover0.480.30.5417
Slightly volatile
Graham Number21.4422.5795.2685
Slightly volatile
Capex Per Share0.03680.03870.5156
Slightly volatile
Revenue Per Share0.230.241.3785
Slightly volatile
Interest Debt Per Share0.480.50.5743
Pretty Stable
Debt To Assets0.0310.0570.0203
Slightly volatile
Days Of Payables Outstanding860734791
Very volatile
Ebt Per Ebit1.050.91680.9763
Pretty Stable
Quick Ratio50.4729.2653.0762
Slightly volatile
Net Income Per E B T0.810.790.9051
Very volatile
Cash Ratio5.195.4641.2126
Slightly volatile
Days Of Sales Outstanding7901.2 K746
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.161.171.0571
Slightly volatile
Fixed Asset Turnover0.410.432.0548
Slightly volatile
Debt Ratio0.0310.0570.0203
Slightly volatile
Price Sales Ratio45.1747.55160
Slightly volatile
Asset Turnover0.0380.03480.0778
Slightly volatile

Relay Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.1 B1.2 B683 M
Slightly volatile

Relay Fundamental Market Drivers

Cash And Short Term Investments750.1 M

Relay Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Relay Therapeutics Financial Statements

Relay Therapeutics investors use historical fundamental indicators, such as Relay Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Relay Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue17.1 M18 M
Total Revenue29.4 M20.6 M
Cost Of Revenue6.1 M4.3 M
Stock Based Compensation To Revenue 3.03  2.88 
Sales General And Administrative To Revenue 2.64  2.51 
Research And Ddevelopement To Revenue 11.63  11.05 
Capex To Revenue 0.15  0.14 
Revenue Per Share 0.24  0.23 
Ebit Per Revenue(16.79)(17.63)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CRMSalesforce
CCitigroup
GMGeneral Motors

Additional Tools for Relay Stock Analysis

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY